Iovance Biotherapeutics, Inc. (IOVA)
Market Cap | 831.50M |
Revenue (ttm) | 212.68M |
Net Income (ttm) | -375.36M |
Shares Out | 333.93M |
EPS (ttm) | -1.23 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 22,367,106 |
Open | 2.260 |
Previous Close | 2.230 |
Day's Range | 2.260 - 2.660 |
52-Week Range | 1.639 - 12.505 |
Beta | 0.85 |
Analysts | Buy |
Price Target | 12.22 (+390.76%) |
Earnings Date | Aug 7, 2025 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops... [Read more]
Financial Performance
In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $12.22, which is an increase of 390.76% from the latest price.
News

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revi...

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
LOS ANGELES , July 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violatio...

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focu...

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.
SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before the July 14, 2025 securities fraud class action deadline.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquire...

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman
IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before the July 14, 2025 securities fraud class action deadline.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA
NEW YORK , June 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA durin...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman
SAN FRANCISCO, June 18, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Finan...

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...

IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 14 Deadline (NASDAQ:IOVA)
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

IOVA LAWSUIT: Iovance Biotherapeutics, Inc. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and c...

IOVA STOCK NOTICE: Iovance Biotherapeutics, Inc. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 14 Legal Deadline
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ...